Back to Research Hub
Vericel Corporation
VCEL
$37.03+1.26 (+3.52%)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
StreetsValue research for Vericel Corporation (VCEL)
Members get the full report for Vericel Corporation: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.